Cryopyrin-associated Periodic Syndromes (CAPS) Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-32), Investigates DelveInsight

As per DelveInsight, the Cryopyrin-associated Periodic Syndromes (CAPS) Market is set to grow in the coming years owing to the expected improvement in the diagnosis rate, advancement in treatment strategies, growth in Research and Development activities, readily uptake of current as well as emerging therapies with patient convenient RoA and increasing awareness about the disease.

DelveInsight's "Cryopyrin-associated Periodic Syndromes (CAPS) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cryopyrin-associated Periodic Syndromes Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Cryopyrin-associated Periodic Syndromes market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Cryopyrin-associated Periodic Syndromes (CAPS): An Overview
Cryopyrin-associated Periodic Syndromes (CAPS) is a rare group of auto-inflammatory as well as known autosomal dominant disorder that is believed to be caused due to a mutation on the exon 3 of the NLRP3 gene which codes for Cryopyrin protein.

CAPS comprises a group of three disorders, varying with their severity and the organs they tend to affect upon the onset, namely Neonatal Onset Multisystem Inflammatory Disease (NOMID), also called as ChronicInflammatory Neurological Cutaneous Articular Syndrome (CINCA), Familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).

It is observed that FCAS has a higher prevalence in North America, which may be elucidated by the pattern of inheritance and diagnostic criteria and terminology applied in the United States vs. Europe. In contrast, only a few patients with FCAS are recognized in Europe, while suggestively more MWS patients are known.

Cryopyrin-associated Periodic Syndromes (CAPS) Market Key Facts
• In 2019, the overall market size of CAPS in the United States was observed to be around USD 35 million. Among the approved therapies in the United States, Rilonacept generated nearly USD 14 million in 2019.
• In 2019, the total prevalent cases of CAPS in the United States were 674, which is anticipated to increase by 2032.
• According to Orphanet (2020), the whole spectrum of CAPS has a prevalence of 1/360,000 in France, CINCA being the less common form. Males and females are equally affected.
• According to NHS England, the prevalence of CAPS is thought to be ~ 1 in 1 million in the United Kingdom.
• Some of the key companies such as Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics, Mabpharm, Ventyx Biosciences, and others are actively working in the CAPS Therapeutics Market to improve the treatment scenario.
• The emerging therapies in the CAPS Therapeutic market include Zunsemetinib (Aclaris Therapeutics), DFV890 (Novartis), ZYIL 1 (Zydus Cadila), IZD334 (Inflazome), VTX2735 (Ventyx Biosciences), and others.

Cryopyrin-associated Periodic Syndromes (CAPS) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted CAPS market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the CAPS market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Cryopyrin-associated Periodic Syndromes Market will Grow by 2032:
https://www.delveinsight.com/report-store/cryopyrin-associated-periodic-syndromes-caps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Cryopyrin-associated Periodic Syndromes (CAPS) Epidemiology
The epidemiology section covers detailed insights into the historical and current Cryopyrin-associated Periodic Syndromes patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the CAPS Epidemiology, Segmented by -
• Total Prevalent Cases of CAPS
• Total Diagnosed Prevalent Cases of CAPS
• Severity-specific Prevalent Cases of CAPS
• Type-specific Prevalent Cases of CAPS
• Age-Specific Prevalent Cases of CAPS
• Treated cases of CAPS

Cryopyrin-associated Periodic Syndromes (CAPS) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CAPS market or expected to get launched in the market during the study period. The analysis covers Cryopyrin-associated Periodic Syndromes market uptake by drugs, patient uptake by therapies, and sales of each drug.

Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. The report also covers the CAPS Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cryopyrin-associated Periodic Syndromes (CAPS) Therapeutics Assessment
Although there are some treatment options available for CAPS, there is still a major requirement to recognize the significant unmet need for effective treatment options for CAPS. To overcome this major unmet need, several pharma giants are working towards the development of a better treatment approach for CAPS patients.

Some of the key Companies in the Cryopyrin-associated Periodic Syndromes (CAPS) Therapeutics Market Include:
• Zydus Cadila
• Novartis
• Inflazome
• Roche
• Aclaris Therapeutics
• Mabpharm
• Ventyx Biosciences
And many others

Cryopyrin-associated Periodic Syndromes (CAPS) Therapies Covered in the Report Include:
• Zunsemetinib : Aclaris Therapeutics
• DFV890: Novartis Pharmaceuticals
• ZYIL 1 : Zydus Cadila
• IZD334: Inflazome
• VTX2735: Ventyx Biosciences
And many more

Learn More About the Emerging Therapies & Key Companies in the Cryopyrin-associated Periodic Syndromes Therapeutics Market:
https://www.delveinsight.com/sample-request/cryopyrin-associated-periodic-syndromes-caps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cryopyrin-associated Periodic Syndromes Competitive Intelligence Analysis
4. Cryopyrin-associated Periodic Syndromes Market Overview at a Glance
5. Cryopyrin-associated Periodic Syndromes Disease Background and Overview
6. Cryopyrin-associated Periodic Syndromes Patient Journey
7. Cryopyrin-associated Periodic Syndromes Epidemiology and Patient Population
8. Cryopyrin-associated Periodic Syndromes Treatment Algorithm, Current Treatment, and Medical Practices
9. Cryopyrin-associated Periodic Syndromes Unmet Needs
10. Key Endpoints of Cryopyrin-associated Periodic Syndromes Treatment
11. Cryopyrin-associated Periodic Syndromes Marketed Products
12. Cryopyrin-associated Periodic Syndromes Emerging Therapies
13. Cryopyrin-associated Periodic Syndromes Seven Major Market Analysis
14. Attribute Analysis
15. Cryopyrin-associated Periodic Syndromes Market Outlook (7 major markets)
16. Cryopyrin-associated Periodic Syndromes Access and Reimbursement Overview
17. KOL Views on the Cryopyrin-associated Periodic Syndromes Market.
18. Cryopyrin-associated Periodic Syndromes Market Drivers
19. Cryopyrin-associated Periodic Syndromes Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/cryopyrin-associated-periodic-syndromes-caps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:

Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.